Author:
Calzetta Luigino,Cazzola Mario,Gholamalishahi Shima,Rogliani Paola
Reference39 articles.
1. Ensifentrine, a novel PDE3 and PDE4 inhibitor for the treatment of COPD: randomized, double-blind, placebo-controlled, multicenter, Phase III trials (The ENHANCE Trials);Anzueto;Am. J. Respir. Crit. Care Med.,2023
2. The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2- aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisoprop;Boswell-Smith;J. Pharmacol. Exp. Therapeut.,2006
3. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone;Calzetta;J. Pharmacol. Exp. Therapeut.,2013
4. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone;Calzetta;J. Pharmacol. Exp. Therapeut.,2013
5. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways;Calzetta;Pulm. Pharmacol. Ther.,2015
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献